Comparison of cardiovascular, cancer and herpes zoster risk of tofacitinib versus etanercept: single-centre observational study

Rheumatology (Oxford). 2022 Aug 30;61(9):e267-e269. doi: 10.1093/rheumatology/keac226.

Authors

Emre Bilgin¹, Emine Duran¹, Erdinç Ünaldı¹, Umut Kalyoncu¹, Sedat Kiraz¹, İhsan Ertenli¹

Affiliation

¹ Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey.

PMID: 35394013
DOI: 10.1093/rheumatology/keac226

No abstract available

Publication types

Observational Study
Letter

MeSH terms

Etanercept / adverse effects
Herpes Zoster* / chemically induced
Herpes Zoster* / epidemiology
Herpesvirus 3, Human
Humans
Neoplasms*
Piperidines / adverse effects
Pyrimidines
Pyrroles / adverse effects

Substances

Piperidines
Pyrimidines
Pyrroles
tofacitinib
Etanercept